All In Biotech

Drug Trial Radar · NCT07823049

Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy

A Randomized, Double-blind, Multicenter Phase III Clinical Study Comparing XNW28012 Versus Placebo in Combination With Best Supportive Care in Patients With Metastatic Pancreatic Cancer Who Have Received Prior Systemic Therapy

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 226 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

226

Planned (sponsor's estimate)

Start

Jul 8, 2025

Primary completion

May 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Evopoint Biosciences Inc.Industry
Sponsor type
Industry
First posted
Sep 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was a randomized, double-blind, multicenter phase III clinical study. A total of 226 patients with metastatic pancreatic ductal carcinoma who had failed or were intolerant to two previous standard therapies were planned.Subjects will be randomized in a 2:1 ratio to either the experimental group or the control group:Experimental Group: XNW28012 for Injection (2.4 mg/kg, administered once every 3 weeks);Control group: XNW28012 mimetic for Injection (administered once every 3 weeks).Both experimental and control subjects will receive optimal supportive care, including but not limited to nutritional support, adjustment of electrolyte balance, and cancer pain support treatment.

Conditions

  • Pancreatic Cancer

Interventions

  • XNW28012 for injectionDrug

    XNW28012 for Injection (2.4 mg/kg, administered once every 3 weeks)

  • XNW28012 Mimetic for InjectionDrug

    XNW28012 Mimetic for Injection (administered once every 3 weeks)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The time from the date of subject enrollment to the date of death from any causeTime frame: through study completion, an average of 2 year

Locations

48 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China · Recruiting

  • Beijing Tsinghua Changgung Hospital

    Beijing, China · Recruiting

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

  • Affiliated Hospital of Binzhou Medical College

    Binzhou, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, China · Recruiting

  • The First People's Hospital of Changzhou

    Changzhou, China · Recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, China · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, China · Recruiting

  • Fuyang Cancer Hospital

    Fuyang, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Recruiting

  • Union Hospital Affiliated to Fujian Medical University

    Fuzhou, China · Recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Ha’erbin, China · Recruiting

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, China · Recruiting

  • The First Hospital of Jilin University

    Jilin City, China · Recruiting

  • Cancer Hospital Affiliated to Shandong First Medical University

    Jinan, China · Recruiting

  • Jinan Central Hospital

    Jinan, China · Recruiting

  • Gansu Provincial Cancer Hospital

    Lanzhou, China · Recruiting

  • Meizhou People's Hospital

    Meizhou, China · Recruiting

  • Jiangxi Provincial Cancer Hospital

    Nanchang, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • Jiangsu Cancer Hospital

    Nanjing, China · Recruiting

  • Jiangsu Provincial People's Hospital

    Nanjing, China · Recruiting

  • Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University

    Nanjing, China · Recruiting

  • Tumor Hospital Affiliated to Guangxi Medical University

    Nanning, China · Recruiting

  • Peking University Cancer Hospital Inner Mongolia Hospital

    Neimeng, China · Recruiting

  • People's Hospital Affiliated to Ningbo University

    Ningbo, China · Recruiting

  • Shanghai East Hospital

    Shanghai, China · Recruiting

  • Shanghai Fourth People's Hospital

    Shanghai, China · Recruiting

  • Zhongshan Hospital, Fudan University

    Shanghai, China · Recruiting

  • Liaoning Cancer Hospital

    Shenyang, China · Recruiting

  • The First Affiliated Hospital of China Medical University

    Shenyang, China · Recruiting

  • Shanxi Cancer Hospital

    Taiyuan, China · Recruiting

  • The First Hospital of Shanxi Medical University

    Taiyuan, China · Recruiting

  • Tianjin Cancer Hospital

    Tianjin, China · Recruiting

  • Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China · Recruiting

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.